Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bank of America Corp (BAC), Johnson & Johnson (JNJ): The Most and Least Shorted Dow Stocks

Page 1 of 2

Short-selling is a vital component of healthy equity markets. Shorts may not be popular, but they help keep Mr. Market on his toes. Even our own Motley Fool CAPS system emulates buying and shorting via thumbs-up and thumbs-down calls, because a bearish investment thesis that you can’t take action on is no thesis at all.

Pick a stock, any stock at all, and somebody out there will have sold a few shares short. Some tickers attract bears because their valuation is running away from reality (as the bears see it, anyway). Other times, shorting can be a simple hedge against drastic market swings.

Not even the Dow Jones Industrial Average‘s elite club of 30 blue-chip giants is immune to shorting.

Bank of America Corp (NYSE:BAC)Examples, please!
Bank of America Corp (NYSE:BAC) is currently the least shorted Dow stock. It would take about a full day at average volume to cover every short bet on the megabank right now. The stock has gained 39% over the last year on a dividend-adjusted basis, crushing the Dow’s 11% gain. And it did this without attracting a den of bears. That’s a testament to how far the stock had been depressed before this huge skyward run. Even the pessimists can’t find much to complain about.

At the other end of the spectrum, you’ll find Johnson & Johnson (NYSE:JNJ) fighting off short-sellers tooth and nail. Covering these bearish bets in a hurry would absorb nearly 10 days of J&J’s average trading volume. That’s more than twice the “days to cover” of the second-place finisher.

The health care titan has beaten the Dow with a 21% one-year price gain, but not without controversy. The company is currently under fire for a large-scale recall of hip replacement devices. Analyst firm Credit Suisse recently downgraded the stock from a “neutral” recommendation to “underperform,” citing overheated valuations relative to other medical stocks. Many bears agree, and 3.7% of J&J’s market float was sold short two weeks ago.

All that and a bag of chips
In second place, semiconductor veteran Intel Corporation (NASDAQ:INTC) would cover its shorts in 4.5 regular trading days, with 4.2% of its shares having been bet on bearish outcomes. And it’s not a valuation play at all: Intel shares have lost 21% of their value year over year, and they trade for less than 10 times trailing and forward earnings.

Intel is the victim of a rapidly changing market, both in enterprise-class computing and consumer devices. Tablets and smartphones are pulling the rug out from under regular laptops and desktops. Intel is late to the mobile game, so this change hurts until the company can get traction for smartphone strategy.

On the other hand, the same trend also fuels a rolling boil under the server segment. All of these mobile gadgets are pretty useless unless you feed them apps, songs, movies, and other data from a data center somewhere. Let’s say Intel’s mobile ambitions don’t work out. That still leaves the company with a vibrant server market.

Smaller rival Advanced Micro Devices, Inc.(NYSE:AMD) used to be a threat in that space but is fading in Intel’s rearview mirror due to weak execution and some boneheaded management moves.  ARM Holdings plc (ADR) (NASDAQ:ARMH) wants to expand its mobile dominance into the data center as well, but it’s hard to find an ARM-powered server system today.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!